Quantitative analysis on the characteristics of targets with FDA approved drugs
<p>Accumulated knowledge of genomic information, systems biology, and disease mechanisms provide an unprecedented opportunity to elucidate the genetic basis of diseases, and to discover new and novel therapeutic targets from the wealth of genomic data. With hundreds to a few thousand potential...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ivyspring International Publisher
2008-01-01
|
| Series: | International Journal of Biological Sciences |
| Online Access: | http://www.biolsci.org/v04p0015.htm |
| _version_ | 1817977236183056384 |
|---|---|
| author | Meena K. Sakharkar, Peng Li, Zhaowei Zhong, Kishore R. Sakharkar |
| author_facet | Meena K. Sakharkar, Peng Li, Zhaowei Zhong, Kishore R. Sakharkar |
| author_sort | Meena K. Sakharkar, Peng Li, Zhaowei Zhong, Kishore R. Sakharkar |
| collection | DOAJ |
| description | <p>Accumulated knowledge of genomic information, systems biology, and disease mechanisms provide an unprecedented opportunity to elucidate the genetic basis of diseases, and to discover new and novel therapeutic targets from the wealth of genomic data. With hundreds to a few thousand potential targets available in the human genome alone, target selection and validation has become a critical component of drug discovery process. The explorations on quantitative characteristics of the currently explored targets (those without any marketed drug) and successful targets (targeted by at least one marketed drug) could help discern simple rules for selecting a putative successful target. Here we use integrative <i>in silico</i> (computational) approaches to quantitatively analyze the characteristics of 133 targets with FDA approved drugs and 3120 human disease genes (therapeutic targets) not targeted by FDA approved drugs. This is the first attempt to comparatively analyze targets with FDA approved drugs and targets with no FDA approved drug or no drugs available for them. Our results show that proteins with 5 or fewer number of homologs outside their own family, proteins with single-exon gene architecture and proteins interacting with more than 3 partners are more likely to be targetable. These quantitative characteristics could serve as criteria to search for promising targetable disease genes.</p> |
| first_indexed | 2024-04-13T22:14:08Z |
| format | Article |
| id | doaj.art-64c6c127395d4acc9c6c19b00fca4df4 |
| institution | Directory Open Access Journal |
| issn | 1449-2288 |
| language | English |
| last_indexed | 2024-04-13T22:14:08Z |
| publishDate | 2008-01-01 |
| publisher | Ivyspring International Publisher |
| record_format | Article |
| series | International Journal of Biological Sciences |
| spelling | doaj.art-64c6c127395d4acc9c6c19b00fca4df42022-12-22T02:27:37ZengIvyspring International PublisherInternational Journal of Biological Sciences1449-22882008-01-01411522Quantitative analysis on the characteristics of targets with FDA approved drugsMeena K. Sakharkar, Peng Li, Zhaowei Zhong, Kishore R. Sakharkar<p>Accumulated knowledge of genomic information, systems biology, and disease mechanisms provide an unprecedented opportunity to elucidate the genetic basis of diseases, and to discover new and novel therapeutic targets from the wealth of genomic data. With hundreds to a few thousand potential targets available in the human genome alone, target selection and validation has become a critical component of drug discovery process. The explorations on quantitative characteristics of the currently explored targets (those without any marketed drug) and successful targets (targeted by at least one marketed drug) could help discern simple rules for selecting a putative successful target. Here we use integrative <i>in silico</i> (computational) approaches to quantitatively analyze the characteristics of 133 targets with FDA approved drugs and 3120 human disease genes (therapeutic targets) not targeted by FDA approved drugs. This is the first attempt to comparatively analyze targets with FDA approved drugs and targets with no FDA approved drug or no drugs available for them. Our results show that proteins with 5 or fewer number of homologs outside their own family, proteins with single-exon gene architecture and proteins interacting with more than 3 partners are more likely to be targetable. These quantitative characteristics could serve as criteria to search for promising targetable disease genes.</p>http://www.biolsci.org/v04p0015.htm |
| spellingShingle | Meena K. Sakharkar, Peng Li, Zhaowei Zhong, Kishore R. Sakharkar Quantitative analysis on the characteristics of targets with FDA approved drugs International Journal of Biological Sciences |
| title | Quantitative analysis on the characteristics of targets with FDA approved drugs |
| title_full | Quantitative analysis on the characteristics of targets with FDA approved drugs |
| title_fullStr | Quantitative analysis on the characteristics of targets with FDA approved drugs |
| title_full_unstemmed | Quantitative analysis on the characteristics of targets with FDA approved drugs |
| title_short | Quantitative analysis on the characteristics of targets with FDA approved drugs |
| title_sort | quantitative analysis on the characteristics of targets with fda approved drugs |
| url | http://www.biolsci.org/v04p0015.htm |
| work_keys_str_mv | AT meenaksakharkarpenglizhaoweizhongkishorersakharkar quantitativeanalysisonthecharacteristicsoftargetswithfdaapproveddrugs |